Aug 26, 2025
BrainsWay: Deep TMS Features Traction, However Valuation Leaves Little Room For Error
BrainsWay: Deep TMS Features Traction, However Valuation Leaves Little Room For Error
seen from United States
seen from United States
seen from United States
seen from United States
seen from China
seen from Türkiye
seen from United States
seen from Malaysia
seen from Bahrain
seen from United States
seen from Finland
seen from United States
seen from China
seen from United States
seen from United States
seen from United States
seen from Sweden
seen from Argentina
seen from United States
seen from Uruguay
BrainsWay: Deep TMS Features Traction, However Valuation Leaves Little Room For Error
BrainsWay: Deep TMS Features Traction, However Valuation Leaves Little Room For Error
BrainsWay Ltd. (BWAY) Q2 2025 Earnings Name Transcript
BrainsWay Ltd. (NASDAQ:BWAY) Q2 2025 Earnings Convention Name August 13, 2025 8:30 AM ET Firm Members Hadar Levy – Chief Government OfficerIdo Marom – Chief Monetary Officer Convention Name Members Carl Edward Byrnes – Northland Capital Markets, Analysis DivisionJeffrey Scott Cohen – Ladenburg Thalmann & Co. Inc., Analysis DivisionGarth Russell – Unidentified Firm Operator Good day, and welcome…
Global Transcranial Magnetic Stimulators (TMS) Market is Expected to Boom Worldwide by 2025 | Find out with the latest research available at Acquire Market Research
Global Transcranial Magnetic Stimulators (TMS) Market is Expected to Boom Worldwide by 2025 | Find out with the latest research available at Acquire Market Research
The Global Transcranial Magnetic Stimulators (TMS) Marketresearch report delivers a sweeping analysis of the current and futuristic growth of the industry that will assist clients, market players, potential and investors to make further business decisions accordingly. The report involves valuable insights into the market size, share, revenue, sales volume, attractiveness, and CAGR. The report…
View On WordPress
Global Narcissism Drug Market Research Reports, Business Risk Analysis 2019 With Bristol-Myers Squibb Company, Otsuka Holdings Co. Ltd, Johnson & Johnson Services, Inc, INSIGHTEC Ltd, Brainsway Ltd, Virtually Better Inc, AbbVie Inc, Medtronic & Others
Global Narcissism Drug Market Research Reports, Business Risk Analysis 2019 With Bristol-Myers Squibb Company, Otsuka Holdings Co. Ltd, Johnson & Johnson Services, Inc, INSIGHTEC Ltd, Brainsway Ltd, Virtually Better Inc, AbbVie Inc, Medtronic & Others
Global narcissism drug market is growing at a steady CAGR in the forecast period of 2019-2026. The report contains data of the base year 2018 and historic year 2017. This rise in market value can be attributed to the Growing awareness regarding narcissism amongst people, increase in initiatives by government and non-government organizations regarding mental disorders by awareness campaigns and…
View On WordPress
BrainsWay Device for Non-Invasive Treatment of OCD Gets FDA Approval
BrainsWay Device for Non-Invasive Treatment of OCD Gets FDA Approval
BrainsWay Device for Non-Invasive Treatment of OCD Gets FDA Approval
By NoCamels Team August 19, 2018
“This article was re-published with permission from NoCamels.com – Israeli Innovation News.
Israeli brain tech startup BrainsWay, which uses deep transcranial magnetic technologies (deep TMS) in the treatment of brain disorders, announced Sunday it has…
View On WordPress
(Part VII) Magnetic Field Stimulation Now Weaponized
(Part VII) Magnetic Field Stimulation Now Weaponized
This is not the article I planned on writing. I rarely procure such strong pause and take an entirely new direction on a theory I have supported. My direction was to continue providing evidence on how the ebb and flow of magnetic fields has varying effects on humans. I can say as a result of a weakening magnetic field – the outcome is not unified. Some may experience a measured feeling of…
View On WordPress
This Will Blow Your Mind: Brainsway’s Magnetic Pulses Helmet Relieves Depression, Obesity
By Betty Ilovici, NoCamels March 08, 2015
A new medical technology designed to treat a range of conditions is gaining momentum in the world of psychiatry, potentially relieving depression, post-traumatic stress disorder (PTSD), addiction, obesity and epilepsy. Deep TMS stimulates brain regions using brief magnetic pulses, and has been shown to trigger a response in 38 percent of severely depressed patients, according to recent studies.
According to the CDC, 3 to 4 percent of American adults suffer from major depression. For those seeking help beyond psychotherapy and psychiatric medication, Deep TMS might provide an alternative treatment.
Developed by Israeli company Brainsway, Deep TMS stimulates relevant areas of the brain with a non-invasive treatment using electro-magnetic waves which run through a special helmet. Founded in Jerusalem by Dr. Yiftach Roth and Dr. Abraham Zangen in 2003, Brainsway considers Deep TMS to be its flagship technology, and claims its has no systemic side effects. “The company’s vision is to bring a new perspective to brain therapy and to open new possibilities for noninvasive effects on brain networks,” Roth, Brainsway’s chief scientist, tells NoCamels.
The FDA has provided approval for Deep TMS since studies conducted by the company have shown positive effects: the response rate was 38.4 percent, meaning patients showed dramatic reduction in symptoms. Most importantly, some of these participants did not respond to medications and other treatments. According to Brainsway, the outpouring of gratitude from such patients has been immense, many of whom considered themselves dysfunctional prior to the treatment. “Knowing that something we developed brings so much relief to so many people is very rewarding,” Roth says.
Non-invasive, patient-friendly treatment
During treatment, the patient wears a helmet that has coils (metal wires), through which currents run and create an electromagnetic field in the brain. The shape of the coil determines the distribution of the electromagnetic field that it produces, penetrating the brain in a non-invasive way. When the coil is placed above the motor cortex of the brain, the area that controls movement, the magnetic pulses cause movement in the hands or the legs by activating neurons that control these specific muscles.
In the same way, doctors use Deep TMS to affect neurons responsible for higher functions of the brain, giving them repeated pulses, thus causing changes in the networks that are related to a variety of conditions, ranging from depression, to obesity and addiction. For example, the coil could be placed to affect the part of the brain that is responsible for drug craving, while also targeting the part of the brain that is responsible for inhibitory control, thus potentially reducing the need for the drug, while increasing the ability to stop substance abuse.
Ongoing research into the effects of Deep TMS on Alzheimer’s disease
While Brainsway continues to develop Deep TMS, studies are taking place around the globe: in Israel, there are various ongoing studies of depression, obsessive-compulsive disorder (OCD), PTSD, Alzheimer’s disease and attention deficit hyperactivity disorder (ADHD).
In the US, Deep TMS has been granted FDA approval for the treatment of major depression; however, studies are still ongoing for approval of treatment for OCD, bipolar disorder, multiple sclerosis and autism. Researchers at Columbia University study Brainsway’s treatment of cocaine addicts, and Harvard University is conducting a study on children with epilepsy.
Since it would take years of research to find the optimal pattern of magnetic pulses to optimize treatment, Brainsway is developing a more advanced, multi-channel helmet, which will combine stimulation from different coils to further target brain regions and personalize treatment. Potentially, the helmet will combine data from other scans, such as the basic brain MRI.
However, some people are still wary about Deep TMS because it reminds them of electric shock therapy (ECT). ECT, which is used to treat mental illnesses, has gotten its share of controversy over the past century, during which it has been portrayed in popular culture as disturbing and painful. The film “One Flew over the Cuckoo’s Nest,” for example, painfully depicts ECT in the famous scene of a patient (played by actor Jack Nicholson) strapped down, writhing in pain, while in shock therapy. Zangen and Roth stress that Deep TMS uses brief magnetic pulses, as opposed to the notorious Electroconvulsive Therapy (ECT), which is based on electrically induced seizures. Brainsway also claims that while ECT requires anesthesia and has severe side effects, including memory loss, Deep TMS does not involve seizures, anesthesia, has no effects on memory, and is well tolerated.
The future goal of Brainsway is to further increase the rate of success in patients who do not respond to medication, or who cannot tolerate the side effects of medication, and ideally, to help patients reach 100 percent remission, using individualized brain therapy.
Photos and video courtesy of Brainsway
Brainsway
The Israeli company Brainsway has developed a device that transmits transcranial magnetic stimulation (TMS), which involves the application of brief magnetic impulses to the brain. TMS has been found to be effective in a wide range of neurological disorders including Parkinson’s, MS, PTSD, autism, Alzheimer’s, alcoholism, and tinnitus. United Health Group, a US insurer with members in 125 other countries that has reported 2013 revenues of $122.5 billion, has approved its use in the treatment of major depressive disorders. The treatment, which was approved by the FDA in January 2013, has no side effects, according to Brainsway, with “the most prominent sensation felt by the patient during treatment [being] a small vibration of the coil elements over the head.” (Times of Israel) It is being made available to patients who have not responded to other antidepressant treatments.